HC-1902 is under clinical development by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) and currently in Phase III for Hypertension. According to GlobalData, Phase III drugs for Hypertension have a 49% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how HC-1902’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HC-1902 overview
Clevidipine butyrate (HC1902) is under development for hypertensive emergencies. The drug candidate is administered by intravenous route in the form of emulsion. It is a dihydropyridine L-type calcium channel blocker.
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) overview
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) (CSPC Zhongnuo) is a pharmaceutical company. It is one of the largest manufacturers of unpatented drugs in China. The company manufactures active pharmaceutical ingredients (APIs) and formulations of several drug categories including antibiotics, gastrointestinal drugs, cardiovascular products, antipyretics, analgesics, vitamins and others. The company exports its products to more than 50 countries across Africa, Southeast Asia, the Middle East, South America and Europe, among others. It also offers original equipment manufacturing (OEM) services to other companies. The company supplies its products to Missionpharma, Shalina, Svizera and Sanavita, Mintlab, Clarion, Mapichem and others. CSPC Zhongnuo is an ISO9001:2004, ISO14001:2000, OHSA, COS and GMP certified company. CSPC Zhongnuo is headquartered in Hebei, China.
For a complete picture of HC-1902’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
